

DAFTAR PUSTAKA

1. Erniaty W, Woro O, Handayani K. Faktor Yang Mempengaruhi Keterlambatan Diagnosa Ca Serviks Penderita Masa Kuratif di Semarang. *Public Heal Perspect J*. 2018;2(2):111–6.
2. Shinta N, Surarso B. Terapi mual muntah pasca kemoterapi. *J THT-KL*. 2016;9(2):74–82.
3. Wardani E, Ambarwati W, Suryandari D. Efek samping kemoterapi secara fisik pasien penderita kanker servik. Surakarta: Universitas Muhammadiyah Surakarta; 2014. 97-106 p.
4. Oetami F, Thaha L, Wahiduddin. Psychological Impact of Breast Cancer Treatment in Hospital Dr . Wahidin Sudirohusodo Makassar. Makassar: Universitas Hasanuddin; 2014.
5. JAMA. Chemotherapy-induced peripheral neuropathy. *JAMA Oncol*. 2019;5(5):750.
6. Zajaczkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. *Int J Mol Sci*. 2019;20(6):1–29.
7. Haddani H. Profil penderita kemoterapi yang menderita polineuropati di RSUP Mohammad Hoesin Palembang. *Maj Kedokt Sriwij*. 2019;51(3):117–23.
8. Rahayu D, Heriady Y, Tursina A. Hubungan Lamanya Kemoterapi dengan Risiko Neuropati Perifer pada Pasien Kanker Payudara di RSUD Al-Ihsan Bandung. *SPeSIA*. 2018;822:526–31.
9. Tzatha E, Deangelis LM. Co-morbidity consult: chemotherapy-induced peripheral neuropathy. *Oncology*. 2017;30(3):240–4.
10. Areti A, Yerra VG, Naidu VGM, Kumar A. Oxidative stress and nerve damage: Role in Chemotherapy Induced Peripheral Neuropathy. *Redox Biol*. Elsevier; 2014;2(1):289–95.
11. Nyrop K. Patient-Reported and Clinician-Reported Chemotherapy-Induced Peripheral Neuropathy in Patients With Early Breast Cancer : Current Clinical Practice. *Cancer*. 2019;1–10.
12. Kolb N, Smith A, Singleton J. Chemotherapy Induced Peripheral Neuropathy Symptoms and Fall Risk. *JAMA Neurol*. 2016;73(7):860–6.
13. Galgano M, Toshkezi G, Qiu X, Russell T, Chin L, Zhao L. Traumatic Brain Injury : Current Treatment Strategies and Future Endeavors. *SAGE*. 2017;26(7):1118–30.

14. Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. *Brain Behav.* 2019;9(6):1–10.
15. Bulls HW, Hoogland AI, Kennedy B, James BW, Arboleda BL, Apte S, et al. A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. *Gynecol Oncol.* Elsevier Inc.; 2018;30:1–6.
16. Kalsi T. The Impact of Comprehensive Geriatric Assessment Interventions on Tolerance to Chemotherapy in Older People. *Br J Cancer.* 2015;112.
17. Hurria A. Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults with Cancer. *J Clin Oncol.* 2016;34(20):2366–2371.
18. Marshall TF, Pinto G, Battaglia F, Moss R, Bryan S. Chemotherapy-induced-peripheral neuropathy , gait and fall risk in older adults following cancer treatment. *J Cancer Res Pract.* Elsevier Ltd; 2017;30:1–5.
19. Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, et al. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. *J Clin Oncol.* 2016;34:1–9.
20. Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, et al. Are We Mis-Estimating Chemotherapy- Induced Peripheral Neuropathy? Analysis of Assessment Methodologies from a Prospective, Multinational, Longitudinal Cohort Study of Patients Receiving Neurotoxic Chemotherapy. *BMC Cancer.* 2019;19(132):1–19.
21. National Cancer Institute (2017). Long-term Nerve Damage Possible After Chemotherapy for Breast Cancer. <https://www.cancer.gov/news-events/cancer-currents-blog/2017/peripheral-neuropathy-chemotherapy-breast-cancer> diakses November 2019.
22. WHO (2019). Cancer in the western pacific. <http://www.who.int/westernpasific/health-topics/cancer> diakses November 2019.
23. Seger RW. Studi kasus Osteosarkoma Metastase. *J Widya Med Surabaya.* 2014;2(2):73–81.
24. Kurniawan P, Yusuf M. Proses Metastasis pada Keganasan Kepala dan Leher. *J THT-KL.* 2014;7(1):37–46.
25. Fitriatuzzakiyyah N, Sinuraya RK, Puspitasari IM. Terapi Kanker dengan Radiasi : Konsep Dasar Radioterapi dan Perkembangannya di Indonesia *Cancer Therapy with Radiation : The Basic Concept of Radiotherapy and Its Development in Indonesia.* *J Farm Klin Indones.* 2017;6(4):311–20.

26. National Cancer Institute (2019). Cancer Classification. <https://training.seer.cancer.gov/disease/categories/classification.html> diakses November 2019.
27. WHO (2019). Cancer. <http://www.who.int/news-room/fact-sheets/detail/cancer> diakses November 2019.
28. Kementerian Kesehatan Republik Indonesia (2019). Bulan peduli kanker payudara. [http //www pusdatin kemkes go id/article/view/17020100002/bulan-peduli-kanker-payudara.html](http://www.pusdatin.kemkes.go.id/article/view/17020100002/bulan-peduli-kanker-payudara.html) diakses November 2019.
29. Kementerian Kesehatan Republik Indonesia (2019). Hari kanker sedunia 2019. Kemenkes RI. 2019;1–2.
30. Manik MJ. Kejadian ekstrasvasi obat kemoterapi pada pasien kanker. *J Keperawatan Soedirman*. 2016;11(3):142–9.
31. Neugut A, Prigerson H. Curative, Life-Extending, and Palliative Chemotherapy: New Outcomes Need New Names. *Oncologist*. 2017;22:883–5.
32. Soffiatti R, Trevisan E, Ruda R. Neurologic complications of chemotherapy and other newer and experimental approaches. *Handb Clin Neurol*. 2014;121(3):1199–218.
33. Hameed A, Malik S, Khan SA. Vinca alkaloids induced peripheral neuropathy- case series and review of literature. *Int J Pharmacol Res*. 2016;6(4):157–9.
34. Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. HHS Public Access - Neuropathic Pain. *Nat Rev Dis Prim*. 2017;3:1–45.
35. Aromolaran KA, Goldstein PA. Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy: Cause and effect? *Mol Pain*. 2017;13:1–24.
36. Kerckhove N, Collin A, Condé S, Chaletex C, Pezet D, Balayssac D. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: A comprehensive literature review. *Front Pharmacol*. 2017;8:1–17.
37. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, Macleod MR, et al. Incidence , prevalence , and predictors of chemotherapy-induced peripheral neuropathy : A systematic review and meta-analysis. *Pain. International Association for the Study of Pain*; 2014;155(12):2461–70.
38. Staff N, Grisold W, Windebank A. Chemotherapy-induced peripheral neuropathy: A current review. *Ann Neurol*. 2017;81(6):772–81.
39. Wozniak KM, Vornov JJ, Wu Y, Nomoto K, Littlefield BA, Desjardins C, et al. Sustained accumulation of microtubule-binding chemotherapy drugs in

the peripheral nervous system: correlations with time course and neurotoxic severity. *Cancer Res.* 2017;76(11):3332–9.

40. Schloss JM, Colosimo M, Airey C, Vitetta L. Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency. 2015;6–13.
41. Stettner M, Steinberger D, Hartmann CJ, Pabst T, Konta L, Hartung HP, et al. Isoniazid-induced polyneuropathy in a tuberculosis patient – implication for individual risk stratification with genotyping ? 2015;326:4–7.
42. Shin YS, Yoo S, Park JK. Radiation-induced neuropathic pain successfully treated with systemic lidocaine administration. *J Pain Res.* 2018;11:545–8.
43. Hersh DS, Wadajkar AS, Roberts N, Perez JG, Nina P, Frenkel V, et al. Evolving drug delivery strategies to overcome the blood brain barrier. *Curr Pharm.* 2016;22(9):1177–93.
44. Maj MA, Ma J, Krukowski KN, Kavelaars A, Heijnen CJ. Inhibition of mitochondrial p53 accumulation by PFT- μ prevents cisplatin-induced peripheral neuropathy. *Front Mol Neurosci.* 2017;10:1–13.
45. Redza-dutordoir M, Averill-bates DA. Activation of apoptosis signalling pathways by reactive oxygen species. *BBA - Mol Cell Res.* Elsevier B.V.; 2016;1863(12):2977–92.
46. Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, et al. Oxidative Stress : Harms and Benefits for Human Health. *Oxid Med Cell Longev.* Hindawi; 2017;2017:1–13.
47. Brandolini L, Angelo M, Antonosante A, Cimini A, Allegretti M. Chemokine Signaling in Chemotherapy-Induced Neuropathic Pain. *Int J Mol Sci.* 2019;20:1–13.
48. Rajalakshmi TR, Aravindhababu N, Shanmugam KT, Masthan KMK. DNA adducts-chemical addons. *J Pharm Bioallied Sci.* 2015;7:197–200.
49. Flatters SJL, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. *BJA. The Author(s);* 2017;119(4):737–49.
50. Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain : clinical manifestations and mechanisms. *Lancet Neurol.* Elsevier Ltd; 2014;13(9):924–35.
51. Park HJ. Chemotherapy induced peripheral neuropathic pain. *Korean J Anesthesiol.* 2014;67(1):4–7.
52. Ramdhani A, Sukmarini L. Transcutaneous electric nerve stimulation (TENS) pada pasien diabetes mellitus tipe ii dengan komplikasi painful diabetic neuropathy (PDN). *NurseLine J.* 2016;1(2):198–202.

53. Fillingim RB, King CD, Ribeiro-dasilva MC, Rahim-williams B, Riley JL, Dentistry C. Sex, Gender, and Pain: A Review of Recent Clinical and Experimental Findings. *J Pain*. Elsevier Ltd; 2009;10(5):447–85.
54. Bartley EJ, Fillingim RB. Sex differences in pain : a brief review of clinical and experimental findings. *Br J Anaesthesia*. 2013;111(1):52–8.
55. Aloisi AM. Why We Still Need To Speak About Sex Differences and Sex Hormones in Pain. *Pain Ther*. Springer Healthcare; 2017;6(2):111–4.
56. Republik Indonesia. 1998. Undang-Undang No.13 Tahun 1998 tentang Kesejahteraan Lanjut Usia. In Jakarta;
57. Badan Pusat Statistik. Statistik Penduduk Lanjut Usia 2019. Badan Pus Stat. 2019;1–258.
58. Kiiik S, Sahar J, Permatasari H. Peningkatan kualitas hidup lanjut usia (lansia) di Kota Depok dengan Latihan Keseimbangan. *J Keperawatan Indones*. 2018;21(2):109–16.
59. Stanhope M, Lancaster J. *Public health nursing population centered health care in the community*. Elseiver. 2016;9.
60. Ezendam N. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based profiles registry. *Gynecol Oncol*. 2014;135(3):510–7.
61. Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. *Oncotarget*. 2017;8(23):38022–43.
62. Fipp F. Chemotherapy-induced peripheral neuropathic pain. *Br J Anaesth Educ*. 2016;16(4):115–9.
63. Center for Disease Control and Prevention (2019). National health interview survey. https://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm. diakses November 2019.
64. Ministry of Health Manatu Hauora (2015). Definitions of Smoking Status. <https://www.health.govz.nz/our-work/preventative-health-wellness/tobacco-control/tobacco-control-information-practitioners/definitions-smoking-status>. diakses November 2019.
65. Christelis N. Neuropathy, Neuropathic Pain , and Painful Peripheral Neuropathy. 2017;1–6.
66. Sastroasmoro S, Ismael S. *Dasar-Dasar Metodologi Penelitian Klinis*. 4th ed. Jakarta: CV Sagung Seto; 2011.
67. WHO. Indonesia. International Agency for Research on Cancer; 2018. 1-2.

68. Oemiati R, Rahajeng E, Kristanto AY. Prevalensi Tumor dan Beberapa Faktor yang Mempengaruhi di Indonesia. *Bul Penelit Kesehat*. 2011;39(4):190–204.
69. Song SJ, Min J, Suh SY, Jung SH, Hahn HJ. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. *Support Care Cancer*. Supportive Care in Cancer; 2017;1–8.
70. Maria IL, Sainal AA, Nyorong M. Risiko Gaya Hidup Terhadap Kejadian Kanker Payudara pada Wanita. *J MKMI*. 2017;13(2):157–66.
71. Dolan ME, Charif O El, Wheeler HE, Gamazon ER, Ardeshir-rouhani-fard S, Monahan P, et al. Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. 2017;5757–69.
72. Bray F, Ferlay J, Soerjomataram I. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *Ca Cancer J Clin*. 2018;68:394–424.
73. Kementerian Kesehatan Republik Indonesia (2018). Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Serviks. kanker.kemkes.go.id diakses April 2020.
74. Oosterling A, Boveldt N, Verhagen C. Neuropathic Pain Components in Patients with Cancer: Prevalence, Treatment, and Interference with Daily Activities. *Pain Pract*. 2015;1–9.
75. Couceiro T, Lima L, Coutinho Jr M, Mello P, Ferreira T, Firmino A. Prevalence of neuropathic pain in patients with cancer. *Br J Pain*. 2018;1(3):231–5.
76. Navega MT. Comparison of pain threshold and duration of pain perception in men and women of different ages. *Fisioter Mov*. 2014;1(1):77–84.
77. Zirpoli GR, Mccann SE, Sucheston-campbell LE, Hershman DL, Ciupak G, Davis W, et al. Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial. *JNCI J Natl Cancer Inst*. 2017;109(12):1–8.
78. Mazilu L, Nculeanu DSTĂ, Gheorghe A, Voinea F, Suceveanu A, Uru SPI Ţ, et al. Incidence of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients in Clinical Practice. *Farmacia*. 2019;67(3):472–6.
79. Xia N, Morteza A, Yang F, Cao H, Wang A, Wang A. Review of the role of cigarette smoking in diabetic foot. 2019;10(2).